Details

Autor(en) / Beteiligte

• Morganti, Alessio G., M.D
• Mignogna, Samantha, M.D
• Deodato, Francesco, M.D
• Massaccesi, Mariangela, M.D
• Cilla, Savino, M.P
• Calista, Franco, M.D
• Serafini, Giovanni, M.D
• Digesú, Cinzia, M.D
• Macchia, Gabriella, M.D
• Picardi, Vincenzo, M.D
• Caravatta, Luciana, M.D
• Di Lullo, Liberato, M.D
• Giglio, Gianfranco, M.D
• Sallustio, Giuseppina, M.D
• Piermattei, Angelo, M.P
• Cellini, Numa, M.D
• Valentini, Vincenzo, M.D

Titel

Feasibility Study of Moderately Accelerated Intensity-Modulated Radiotherapy Plus Concurrent Weekly Cisplatin After Induction Chemotherapy in Locally Advanced Head-and Neck Cancer

Ist Teil von

• International journal of radiation oncology, biology, physics, 2011-03, Vol.79 (4), p.1073-1080

Ort / Verlag

New York, NY: Elsevier

Erscheinungsjahr

2011

Quelle

Access via ScienceDirect (Elsevier)

Beschreibungen/Notizen

• Purpose To evaluate the feasibility and efficacy of moderately accelerated intensity-modulated radiation therapy (IMRT) along with weekly cisplatin, after induction chemotherapy, in patients with locally advanced unresectable head and neck cancer (HNC). Methods and Materials Patients with Stage III or IV locally advanced HNC, without progressive disease after three courses of induction chemotherapy, received concurrent chemo-IMRT (weekly cisplatin 30 mg/m2 plus simultaneous integrated boost IMRT). A total of 67.5 Gy in 30 fractions were delivered to primary tumor and involved nodes, 60 Gy in 30 fractions to high-risk nodal areas, and 55.5 Gy in 30 fractions to low-risk nodal areas. Results In all, 36 patients (median age, 56 years) with International Union Against Cancer (UICC) Stage III ( n = 5) and IV ( n = 31) were included. Of the 36 patients, 17 had received CF (cisplatin and 5-fluorouracil (CF) and 19 had received docetaxel cisplatin and 5-fluorouracil (DCF). During concurrent chemoradiation, 11 of 36 patients (30.5%) experienced Grade III mucositis (CF, 47%; DCF, 15%; p < 0.04). Grade III pharyngeal–esophageal toxicity was observed in 5 of 19 patients (26.3%; CF, 0.0%; DCF, 26.3%; p = 0.02). Two patients died of complications (5.5%). After chemoradiation, the complete response rate was 63.8%. Two-year local control was 88.7%. Two-year progression free survival and overall survival were 74.5% and 60.9%, respectively. Conclusions In our experience, a moderately accelerated chemo-IMRT was feasible after induction chemotherapy. However, a noteworthy early death rate of 5.5% was observed. Intensive supportive care strategies should be defined to better manage radiation-induced toxic effects. Longer follow-up is required to determine the incidence of late radiation toxicities and tumor control rates.